The assessment of the economic return from controlled clinical trials: A framework applied to clinical trials of colorectal cancer follow-up

European Journal of Health Economics

Volumn 4, Issue 1, 2003, Pages 6-11

  Coyle, Douglas ^a,b   Grunfel, E ^a,b,c   Wells, G ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Clinical trials; Economic evaluation; Payback

Indexed keywords

ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; COST; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FOLLOW UP; FORECASTING; MEDICAL RESEARCH; METHODOLOGY; MODEL; PREDICTION; PRIORITY JOURNAL;

EID: 0037263366     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-002-0142-5     Document Type: Article

References (25)

1. Young A, Rea D (2000) ABC of colorectal cancer: Treatment of advanced disease. BMJ 321:1278-1281
2. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrerro AM, Prasad M, Blumgart LH, Brennan MF (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938-946
3. Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonal JS, Haller DG, Laurie JA (1998) Surgery for recurrent colon cancer: strategies for identifying respectable recurrence and success rates for resection. Ann Intern Med 129:27-35
4. Schoemaker D, Black R, Giles L,Toouli J (1998) Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 114:7-14
5. Virgo KS,Vernava AM, Longo WE, McKirgan LW, Johnson FE (1995) Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 273:1837-1841
6. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houselingen HC, Habbema DF, van de Velde CJ (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174-82
7. Rossen M,Chan L,Beart RW, Vucasin P, Anthone G (1998) Follow-up of colorectal cancer. A meta-analysis. Dis Colon Rectum 41:1116-1126
8. McArdle C (2000) ABC of colorectal cancer: effectiveness of follow up. BMJ 321:1332-1335
9. Cooper GS, Yuan Z, ChakA,Rimm,AA (1999) Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for nonmetastatic colorectal carcinoma. Cancer 85:2124-2131
10. Vernava AM, Longo, WE, Virgo KS, Coplin MA, Wade TP, Johnson FE (1994) Current follow-up strategies after resection of colon cancer. Dis Colon rectum 37:573-583
11. Beson AB, Desch CE,Glynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Smith TJ, Somerfield MR (2000) 2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines. J Clin Oncol 18:3586-3588
12. Cancer Care Ontario Practice Guidelines Initiative (2000) Follow-up of Patients with "curatively resected"colorectal cancer. Practice-guidelines-in-progress report, 2-9 October
13. Berman JM, Cheung RJ,Weinberg DS (2000) Surveillance after colorectal cancer resection. Lancet 355:395-399
14. National Cancer Institute of Cancer (1999) Canadian cancer statistics 1999. National Cancer Institute of Cancer: Toronto
15. Brown ML, Nayfield SG, Shibley LM (1994) Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 86:424-430
16. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938-946
17. Baladi J-F (1996) A guidance document for the cost process, version 1.0. Canadian Coordinating Office for Health Technology Assessment: Ottawa
18. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, Tugwell P, Konchak R, Hubbard E, Firestone T (1996) Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 9:535-559
19. Laupacis A (2002) Inclusion of drugs in provincial drug benefit programs: Who is making these decisions,and are they the right ones? Can Med Asso J 166:44-47
20. Doubilet P, Begg CB,Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 5:157-177
21. O'Brien BJ (1997) A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Managed Care 3: S33-S40
22. Claxton K (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18:341-364
23. Hornberger J Eghtesady P (1998) The cost-benefit of a randomized trial to a health care organization. Controlled Clin Trials 19:198-211
24. Detsky AS (1990) Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med 9:173-184
25. Townsend J, Buxton MJ (1997) Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy 39:181-194